Press Releases

Filters (1)
March 1, 2021

Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant

Read more
May 21, 2019

Debiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial

Read more
November 3, 2015

Debiopharm International SA presents positive preliminary results from Phase 1 trials in the development of the IAP inhibitor Debio 1143…

Read more
April 16, 2015

Debiopharm International SA announces results of 2 key oncology programs at 2015 AACR Conference

Read more
November 18, 2014

Debiopharm Group™ presents advances of two key oncology clinical programs at the 26th EORTC-NCI-AACR symposium in Barcelona

Read more
May 28, 2014

Debiopharm Group™ moves forward three of its oncology clinical programs and will present the recent progresses at the 50th American…

Read more
June 4, 2013

Debiopharm Group™ announces additional phase I clinical trial evaluating Debio 1143 combined with chemotherapies for patients with selected solid malignancies

Read more
September 7, 2011

Debiopharm and Ascenta Therapeutics, Inc. announce an exclusive license agreement for the development and commercialization of the IAP (Inhibitor of…

Read more